Jin Medical International Stock Beneish M Score

ZJYL Stock   1.06  0.01  0.93%   
This module uses fundamental data of JIN MEDICAL to approximate the value of its Beneish M Score. JIN MEDICAL M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out JIN MEDICAL Piotroski F Score and JIN MEDICAL Altman Z Score analysis.
  
Cash Flow To Debt Ratio is expected to rise to 0.71 this year, although the value of Short and Long Term Debt Total will most likely fall to about 3.5 M. At this time, JIN MEDICAL's Capex To Operating Cash Flow is quite stable compared to the past year. PFCF Ratio is expected to rise to 53.63 this year, although the value of Days Sales Outstanding will most likely fall to 142.82.
At this time, it appears that JIN MEDICAL INTERNATIONAL is an unlikely manipulator. The earnings manipulation may begin if JIN MEDICAL's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by JIN MEDICAL executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of JIN MEDICAL's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.85
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

0.66

Focus
Asset Quality

1.35

Focus
Expense Coverage

1.11

Focus
Gross Margin Strengs

0.95

Focus
Accruals Factor

1.11

Focus
Depreciation Resistance

0.91

Focus
Net Sales Growth

0.93

Focus
Financial Leverage Condition

1.04

Focus

JIN MEDICAL Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if JIN MEDICAL's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables5.3 M8.5 M
Way Down
Slightly volatile
Total Revenue21.3 M22.8 M
Significantly Down
Very volatile
Total Assets27.5 M37.8 M
Way Down
Slightly volatile
Total Current Assets25 M35.8 M
Way Down
Slightly volatile
Non Current Assets Total1.8 M1.6 M
Moderately Up
Slightly volatile
Property Plant Equipment1.7 M1.5 M
Fairly Up
Slightly volatile
Depreciation And Amortization254.1 K198.9 K
Significantly Up
Slightly volatile
Selling General AdministrativeM1.9 M
Sufficiently Up
Slightly volatile
Total Current Liabilities6.8 MM
Fairly Down
Slightly volatile
Short Term Debt3.5 M4.7 M
Way Down
Slightly volatile
Operating Income2.3 M2.6 M
Fairly Down
Slightly volatile
Short Term Investments11.8 M11.2 M
Sufficiently Up
Slightly volatile
Gross Profit Margin0.370.39
Notably Down
Pretty Stable

JIN MEDICAL INTERNATIONAL Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between JIN MEDICAL's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards JIN MEDICAL in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find JIN MEDICAL's degree of accounting gimmicks and manipulations.

About JIN MEDICAL Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

254,148

At this time, JIN MEDICAL's Depreciation And Amortization is quite stable compared to the past year.

JIN MEDICAL Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as JIN MEDICAL. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables7.9M6.0M4.3M4.2M8.5M5.3M
Total Revenue16.2M20.8M19.2M19.8M22.8M21.3M
Total Assets20.8M21.9M20.9M32.9M37.8M27.5M
Total Current Assets18.2M19.4M18.9M31.1M35.8M25.0M
Net Debt983.7K(3.7M)(4.8M)(2.8M)(2.5M)(2.7M)
Operating Income2.4M2.6M2.1M2.9M2.6M2.3M
Investments(2.0M)(1.1M)(120.9K)(7.7M)(7.0M)(6.6M)

About JIN MEDICAL Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze JIN MEDICAL INTERNATIONAL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of JIN MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of JIN MEDICAL INTERNATIONAL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether JIN MEDICAL INTERNATIONAL is a strong investment it is important to analyze JIN MEDICAL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact JIN MEDICAL's future performance. For an informed investment choice regarding JIN Stock, refer to the following important reports:
Check out JIN MEDICAL Piotroski F Score and JIN MEDICAL Altman Z Score analysis.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of JIN MEDICAL. If investors know JIN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about JIN MEDICAL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.12)
Earnings Share
0.02
Revenue Per Share
0.129
Quarterly Revenue Growth
0.03
Return On Assets
0.0403
The market value of JIN MEDICAL INTERNATIONAL is measured differently than its book value, which is the value of JIN that is recorded on the company's balance sheet. Investors also form their own opinion of JIN MEDICAL's value that differs from its market value or its book value, called intrinsic value, which is JIN MEDICAL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because JIN MEDICAL's market value can be influenced by many factors that don't directly affect JIN MEDICAL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between JIN MEDICAL's value and its price as these two are different measures arrived at by different means. Investors typically determine if JIN MEDICAL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, JIN MEDICAL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.